We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$540K
Cap. Flow
+$13.4M
Cap. Flow %
3.48%
Top 10 Hldgs %
70.32%
Holding
34
New
1
Increased
10
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$22M
2
NTLA icon
Intellia Therapeutics
NTLA
+$4.6M
3
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$3.46M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.21M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.81M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$12.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$7.68M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$3.53M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$2.19M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$1.45M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
26
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.38M 0.62%
319,671
– –
PHAT icon
27
Phathom Pharmaceuticals
PHAT
$743M
$1.52M 0.39%
212,615
+16,673
+9% +$146K
INZY
28
DELISTED
Inozyme Pharma
INZY
$1.34M 0.35%
233,728
+3,228
+1% +$8.53K
ONCR
29
DELISTED
Oncorus, Inc.
ONCR
$818K 0.21%
2,377,031
– –
TECX
30
Tectonic Therapeutic
TECX
$696M
$648K 0.17%
53,993
– –
BDTX icon
31
Black Diamond Therapeutics
BDTX
$128M
$274K 0.07%
144,888
– –
HRMY icon
32
Harmony Biosciences
HRMY
$2.28B
– –
-139,377
Closed -$7.68M
PRAX icon
33
Praxis Precision Medicines
PRAX
$9.63B
– –
-40,667
Closed -$1.45M
GTHX
34
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-650,000
Closed -$3.53M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2023 Portfolio in Review

As of Q1 2023, MPM BioImpact held 34 positions worth $385M, down 0.14% from $385M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

MPM BioImpact deployed $13.4M of net new capital in Q1 2023, opening 1 new position and adding to 10 existing holdings. Its largest new stake was Relay Therapeutics: 1,225,634 shares worth $20.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $12.4M trimmed.

  • MPM BioImpact's largest Q1 2023 buy was Relay Therapeutics: 1,225,634 shares worth $20.2M.
  • MPM BioImpact added most to Intellia Therapeutics in Q1 2023, an estimated $4.6M increase.
  • MPM BioImpact's biggest Q1 2023 reduction was uniQure, cutting an estimated $12.4M.
  • MPM BioImpact fully exited Harmony Biosciences in Q1 2023, selling an estimated $7.68M.
  • MPM BioImpact's ten largest holdings make up 70% of its $385M portfolio in Q1 2023.
  • MPM BioImpact opened 1 new position and closed 3 in Q1 2023.
  • MPM BioImpact's portfolio value fell 0.14% quarter-over-quarter to $385M.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.